The content on this site is intended for healthcare professionals only
At a press conference at ASCO 2014, Dr Liu presents her work regarding a new immunotherapy drug combo, cediranib plus olaparib, which has been shown to significantly increase progression-free survival in recurrent ovarian cancer.
Read the article for more.
Zedoresertib plus lunresertib shows promising tumour shrinkage in CCNE1-amplified and FBXW7-mutant cancers
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
OncoAlert round up July 28th to August 3rd, 2023
Gynaecological cancer: New targets and immunotherapy developments
The current status of multiple myeloma diagnosis and treatment
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
